Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 621

1.

Immunotherapy for esophageal cancer: a 2019 update.

Schizas D, Charalampakis N, Kole C, Mylonas KS, Katsaros I, Zhao M, Ajani JA, Psyrri A, Karamouzis MV, Liakakos T.

Immunotherapy. 2020 Mar 24. doi: 10.2217/imt-2019-0153. [Epub ahead of print]

PMID:
32208794
2.

Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.

Song S, Li Y, Xu Y, Ma L, Pizzi MP, Jin J, Scott AW, Huo L, Wang Y, Lee JH, Bhutani MS, Weston B, Shanbhag ND, Johnson RL, Ajani JA.

Mol Oncol. 2020 Mar 16. doi: 10.1002/1878-0261.12667. [Epub ahead of print]

3.

Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer.

Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, Corsini EM, Mok I, Wei X, Yao L, Wang X, Komaki RU, Chang JY, Chun SG, Jeter MD, Swisher SG, Ajani JA, Blum-Murphy M, Vaporciyan AA, Mehran RJ, Koong AC, Gandhi SJ, Hofstetter WL, Hong TS, Delaney TF, Liao Z, Mohan R.

J Clin Oncol. 2020 Mar 11:JCO1902503. doi: 10.1200/JCO.19.02503. [Epub ahead of print]

PMID:
32160096
4.

Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients.

Lopez A, Harada K, Chen HC, Bhutani MS, Weston B, Lee JH, Maru DM, Chin FW, Rogers JE, Thomas I, Amlashi FG, Blum-Murphy MA, Rice DC, Zhao M, Hofstetter WL, Nguyen Q, Ajani JA.

Medicine (Baltimore). 2020 Feb;99(9):e19295. doi: 10.1097/MD.0000000000019295.

5.

Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer.

Rogers JE, Xiao L, Trail A, Blum Murphy M, Palmer M, Ajani JA.

Oncology. 2020 Feb 25:1-6. doi: 10.1159/000505974. [Epub ahead of print]

PMID:
32097933
6.

Staging laparoscopy and peritoneal cytology in patients with early stage gastric adenocarcinoma.

Allen CJ, Blumenthaler AN, Das P, Minsky BD, Blum M, Roy-Chowdhuri S, Ajani JA, Ikoma N, Mansfield PF, Badgwell BD.

World J Surg Oncol. 2020 Feb 17;18(1):39. doi: 10.1186/s12957-020-01813-y.

7.

An improved strategy for CRISPR/Cas9 gene knockout and subsequent wildtype and mutant gene rescue.

Jin J, Xu Y, Huo L, Ma L, Scott AW, Pizzi MP, Li Y, Wang Y, Yao X, Song S, Ajani JA.

PLoS One. 2020 Feb 13;15(2):e0228910. doi: 10.1371/journal.pone.0228910. eCollection 2020.

8.

Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility.

Dragomir MP, Kopetz S, Ajani JA, Calin GA.

Gut. 2020 Apr;69(4):748-763. doi: 10.1136/gutjnl-2019-318279. Epub 2020 Feb 7. Review.

PMID:
32034004
9.

Rare Esophageal Leptomeningeal Metastases Detected on 18F-FDG PET/CT.

Lu Y, Wang L, Ajani JA.

Clin Nucl Med. 2020 Apr;45(4):334-335. doi: 10.1097/RLU.0000000000002952.

PMID:
31977493
10.

The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression.

Lei G, Zhang Y, Koppula P, Liu X, Zhang J, Lin SH, Ajani JA, Xiao Q, Liao Z, Wang H, Gan B.

Cell Res. 2020 Feb;30(2):146-162. doi: 10.1038/s41422-019-0263-3. Epub 2020 Jan 16.

PMID:
31949285
11.

PPAR╬┤ Interacts with the Hippo Coactivator YAP1 to Promote SOX9 Expression and Gastric Cancer Progression.

Song S, Wang Z, Li Y, Ma L, Jin J, Scott AW, Xu Y, Estrella JS, Song Y, Liu B, Johnson RL, Ajani JA.

Mol Cancer Res. 2020 Mar;18(3):390-402. doi: 10.1158/1541-7786.MCR-19-0895. Epub 2019 Dec 3.

PMID:
31796534
12.

The role of hedgehog signaling in gastric cancer: molecular mechanisms, clinical potential, and perspective.

Xu Y, Song S, Wang Z, Ajani JA.

Cell Commun Signal. 2019 Nov 27;17(1):157. doi: 10.1186/s12964-019-0479-3. Review.

13.

Linitis Plastica: a Distinct Type of Gastric Cancer.

Ikoma N, Agnes A, Chen HC, Wang X, Blum MM, Das P, Minsky B, Estrella JS, Mansfield P, Ajani JA, Badgwell BD.

J Gastrointest Surg. 2019 Nov 21. doi: 10.1007/s11605-019-04422-7. [Epub ahead of print]

PMID:
31754987
14.

Endoscopic management of esophageal cancer.

Ahmed O, Ajani JA, Lee JH.

World J Gastrointest Oncol. 2019 Oct 15;11(10):830-841. doi: 10.4251/wjgo.v11.i10.830. Review.

15.

LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma.

Xu Y, Li Y, Jin J, Han G, Sun C, Pizzi MP, Huo L, Scott A, Wang Y, Ma L, Lee JH, Bhutani MS, Weston B, Vellano C, Yang L, Lin C, Kim Y, MacLeod AR, Wang L, Wang Z, Song S, Ajani JA.

Mol Cancer. 2019 Oct 10;18(1):141. doi: 10.1186/s12943-019-1064-5.

16.

Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC).

Rivin Del Campo E, Matzinger O, Haustermans K, Peiffert D, Glynne-Jones R, Winter KA, Konski AA, Ajani JA, Bosset JF, Hannoun-Levi JM, Puyraveau M, Chakravarthy AB, Meadows H, Northover J, Collette L, Christiaens M, Maingon P.

Eur J Cancer. 2019 Nov;121:130-143. doi: 10.1016/j.ejca.2019.08.022. Epub 2019 Sep 28. Review.

PMID:
31574418
17.

Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer.

Chen D, Menon H, Verma V, Seyedin SN, Ajani JA, Hofstetter WL, Nguyen QN, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Barsoumian HB, Erasmus JJ, Lee JH, Bhutani MS, Hess KR, Minsky BD, Welsh JW.

JAMA Oncol. 2019 Sep 17. doi: 10.1001/jamaoncol.2019.2809. [Epub ahead of print]

PMID:
31529018
18.

Ushering in Liquid Biopsy for the Microsatellite Status: Advantages and Caveats.

Wang L, Ajani JA.

Clin Cancer Res. 2019 Dec 1;25(23):6887-6889. doi: 10.1158/1078-0432.CCR-19-2585. Epub 2019 Sep 16.

PMID:
31527165
19.

Gastric cancer in the remnant stomach after pancreaticoduodenectomy: A case series.

Sonoda K, Samdani RT, Ikoma N, Kaya DM, Blum-Murphy M, Ajani JA, Badgwell BD, Katz MH, Rashid A, Estrella JS.

J Surg Oncol. 2019 Dec;120(7):1137-1141. doi: 10.1002/jso.25695. Epub 2019 Sep 9.

PMID:
31498442
20.

Taxane- Versus Cisplatin-Based Chemotherapy With Radiation Therapy Is a Better Platform to Refine Esophageal Cancer Therapy.

Rogers JE, Ajani JA.

J Clin Oncol. 2019 Oct 20;37(30):2805-2806. doi: 10.1200/JCO.19.01247. Epub 2019 Aug 29. No abstract available.

PMID:
31465257
21.

Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.

Yamashita K, Iwatsuki M, Harada K, Eto K, Hiyoshi Y, Ishimoto T, Nagai Y, Iwagami S, Miyamoto Y, Yoshida N, Komohara Y, Ajani JA, Baba H.

Gastric Cancer. 2020 Jan;23(1):95-104. doi: 10.1007/s10120-019-00999-9. Epub 2019 Aug 26.

PMID:
31451991
22.

Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma.

Tong Z, Mejia A, Veeranki O, Verma A, Correa AM, Dokey R, Patel V, Solis LM, Mino B, Kathkuda R, Rodriguez-Canales J, Lin SH, Krishnan S, Kopetz S, Blum M, Ajani JA, Hofstetter WL, Maru DM.

Ther Adv Med Oncol. 2019 Jul 25;11:1758835919864850. doi: 10.1177/1758835919864850. eCollection 2019.

23.

Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy.

Stark AP, Ikoma N, Chiang YJ, Estrella JS, Das P, Minsky BD, Blum MM, Ajani JA, Mansfield P, Badgwell BD.

Ann Surg Oncol. 2019 Oct;26(11):3602-3610. doi: 10.1245/s10434-019-07638-8. Epub 2019 Jul 26.

PMID:
31350645
24.

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, Denlinger CS, Enzinger PC, Fanta P, Farjah F, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Leong S, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Paluri RK, Park H, Perry KA, Pimiento J, Poultsides GA, Roses R, Strong VE, Wiesner G, Willett CG, Wright CD, McMillian NR, Pluchino LA.

J Natl Compr Canc Netw. 2019 Jul 1;17(7):855-883. doi: 10.6004/jnccn.2019.0033.

PMID:
31319389
25.

Morbidity following salvage esophagectomy for squamous cell carcinoma: the MD Anderson experience.

Mitchell KG, Nelson DB, Corsini EM, Vaporciyan AA, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Sepesi B, Walsh GL, Bhutani MS, Maru DM, Wu CC, Nguyen QN, Ajani JA, Swisher SG, Hofstetter WL.

Dis Esophagus. 2020 Mar 16;33(3). pii: doz067. doi: 10.1093/dote/doz067.

PMID:
31313820
26.

Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer?

Yamashita K, Iwatsuki M, Harada K, Koga Y, Kiyozumi Y, Eto K, Hiyoshi Y, Ishimoto T, Iwagami S, Baba Y, Miyamoto Y, Yoshida N, Komohara Y, Ajani JA, Baba H.

Br J Cancer. 2019 Jul;121(3):278-280. doi: 10.1038/s41416-019-0515-5. Epub 2019 Jul 9.

PMID:
31285589
27.

Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin.

Takeuchi M, Ajani JA, Fang X, Pfeiffer P, Takeuchi M, van Laarhoven HWM.

Cancers (Basel). 2019 Jun 21;11(6). pii: E871. doi: 10.3390/cancers11060871.

28.

Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.

Harada K, Hwang H, Wang X, Abdelhakeem A, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Zhao M, Bhutani MS, Nguyen QN, Swisher SG, Ikoma N, Badgwell BD, Hofstetter WL, Ajani JA.

Ann Surg. 2019 Jun 7. doi: 10.1097/SLA.0000000000003383. [Epub ahead of print]

PMID:
31188215
29.

Endoscopic resection for esophageal or gastroesophageal junction adenocarcinoma.

Harada K, Zhao M, Baba H, Ajani JA.

Dig Med Res. 2019 Apr;2. pii: 7. doi: 10.21037/dmr.2019.04.01. Epub 2019 Apr 22. No abstract available.

30.

Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response.

Wang R, Song S, Harada K, Ghazanfari Amlashi F, Badgwell B, Pizzi MP, Xu Y, Zhao W, Dong X, Jin J, Wang Y, Scott A, Ma L, Huo L, Vicente D, Blum Murphy M, Shanbhag N, Tatlonghari G, Thomas I, Rogers J, Kobayashi M, Vykoukal J, Estrella JS, Roy-Chowdhuri S, Han G, Zhang S, Mao X, Song X, Zhang J, Gu J, Johnson RL, Calin GA, Peng G, Lee JS, Hanash SM, Futreal A, Wang Z, Wang L, Ajani JA.

Gut. 2020 Jan;69(1):18-31. doi: 10.1136/gutjnl-2018-318070. Epub 2019 Jun 6.

31.

The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer.

Yin Y, Liu W, Shen Q, Zhang P, Wang L, Tao R, Li H, Ma X, Zeng X, Cheong JH, Song S, Ajani JA, Mills GB, Tao K, Peng G.

Mol Cancer Ther. 2019 Aug;18(8):1439-1450. doi: 10.1158/1535-7163.MCT-18-0833. Epub 2019 May 29.

PMID:
31142662
32.

Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma.

Rogers JE, Xiao L, Amlashi FG, Elimova E, Blum Murphy MA, Sanders E, Shanbhag N, Thomas I, Ajani JA.

Oncology. 2019;96(5):252-258. doi: 10.1159/000496978. Epub 2019 Mar 20.

PMID:
30893708
33.

The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors.

Koga Y, Iwatsuki M, Yamashita K, Kiyozumi Y, Kurashige J, Masuda T, Eto K, Iwagami S, Harada K, Ishimoto T, Baba Y, Yoshida N, Miyanari N, Takamori H, Ajani JA, Baba H.

Gastric Cancer. 2019 Nov;22(6):1100-1108. doi: 10.1007/s10120-019-00950-y. Epub 2019 Mar 11.

PMID:
30854619
34.

SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer.

van den Boorn HG, Abu-Hanna A, Ter Veer E, van Kleef JJ, Lordick F, Stahl M, Ajani JA, Guimbaud R, Park SH, Dutton SJ, Bang YJ, Boku N, Mohammad NH, Sprangers MAG, Verhoeven RHA, Zwinderman AH, van Oijen MGH, van Laarhoven HWM.

Cancers (Basel). 2019 Feb 5;11(2). pii: E187. doi: 10.3390/cancers11020187.

35.

Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation.

Harada K, Wu CC, Wang X, Mizrak Kaya D, Amlashi FG, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Bhutani MS, Hofstetter WL, Nguyen QN, Ajani JA.

Ann Surg. 2019 Jan 31. doi: 10.1097/SLA.0000000000003228. [Epub ahead of print]

PMID:
30720506
36.

Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.

Shah MA, Kang YK, Thuss-Patience PC, Ohtsu A, Ajani JA, Van Cutsem E, Hoersch S, Harle-Yge ML, de Haas SL.

Gastric Cancer. 2019 Jul;22(4):803-816. doi: 10.1007/s10120-018-00923-7. Epub 2019 Jan 31.

PMID:
30706247
37.

Higher rate of colon polyp detection aided by an artificial intelligent software.

Iwatsuki M, Harada K, Baba H, Ajani JA.

Transl Gastroenterol Hepatol. 2018 Dec 24;3:106. doi: 10.21037/tgh.2018.12.05. eCollection 2018. No abstract available.

38.

Neoadjuvant and adjuvant therapy for gastrointestinal stromal tumors.

Iwatsuki M, Harada K, Iwagami S, Eto K, Ishimoto T, Baba Y, Yoshida N, Ajani JA, Baba H.

Ann Gastroenterol Surg. 2018 Sep 27;3(1):43-49. doi: 10.1002/ags3.12211. eCollection 2019 Jan. Review.

39.

Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy.

Newhook TE, Agnes A, Blum M, Estrella JS, Das P, Ho L, Ajani JA, Minsky BD, Mansfield P, Badgwell BD.

Ann Surg Oncol. 2019 May;26(5):1394-1400. doi: 10.1245/s10434-018-07140-7. Epub 2019 Jan 24.

PMID:
30680477
40.

Targeting Angiogenesis in Colorectal Carcinoma.

Lopez A, Harada K, Vasilakopoulou M, Shanbhag N, Ajani JA.

Drugs. 2019 Jan;79(1):63-74. doi: 10.1007/s40265-018-1037-9. Review.

PMID:
30617958
41.

A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer.

Bang YJ, Kang YK, Ng M, Chung HC, Wainberg ZA, Gendreau S, Chan WY, Xu N, Maslyar D, Meng R, Chau I, Ajani JA.

Eur J Cancer. 2019 Feb;108:17-24. doi: 10.1016/j.ejca.2018.11.017. Epub 2018 Dec 25.

PMID:
30592991
42.

YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer.

Li F, Xu Y, Liu B, Singh PK, Zhao W, Jin J, Han G, Scott AW, Dong X, Huo L, Ma L, Pizzi MP, Wang Y, Li Y, Harada K, Xie M, Skinner HD, Ding S, Wang L, Krishnan S, Johnson RL, Song S, Ajani JA.

Clin Cancer Res. 2019 Apr 1;25(7):2264-2277. doi: 10.1158/1078-0432.CCR-18-1029. Epub 2018 Dec 18.

43.

Cancer stem cells in esophageal cancer and response to therapy.

Harada K, Pool Pizzi M, Baba H, Shanbhag ND, Song S, Ajani JA.

Cancer. 2018 Oct 15;124(20):3962-3964. doi: 10.1002/cncr.31697. Epub 2018 Oct 25. Review. No abstract available.

44.

A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer.

Harada K, Abdelhakeem AAF, Ajani JA.

Nat Rev Clin Oncol. 2019 Jan;16(1):9-10. doi: 10.1038/s41571-018-0108-x. No abstract available.

PMID:
30291292
45.

A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-╬▓ Superfamily.

Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L; Cancer Genome Atlas Research Network, Weinstein JN, Mishra L, Akbani R.

Cell Syst. 2018 Oct 24;7(4):422-437.e7. doi: 10.1016/j.cels.2018.08.010. Epub 2018 Sep 26.

46.

Attenuation of YAP1 can potentially target cancer stem cells to overcome drug resistance.

Harada K, Song S, Ajani JA.

Oncoscience. 2018 Aug 22;5(7-8):214-215. doi: 10.18632/oncoscience.449. eCollection 2018 Jul. No abstract available.

47.

Serum miR-331-3p predicts tumor recurrence in esophageal adenocarcinoma.

Gu J, Zhang J, Zheng L, Ajani JA, Wu X, Ye Y.

Sci Rep. 2018 Sep 18;8(1):14006. doi: 10.1038/s41598-018-32282-9.

48.

Oesophageal preservation in locally advanced oesophageal cancer.

Ajani JA, Bhutani MS, Swisher SG.

Lancet Oncol. 2018 Sep;19(9):e430. doi: 10.1016/S1470-2045(18)30617-X. No abstract available.

PMID:
30191840
49.

Reply.

Song S, Ajani JA.

Gastroenterology. 2018 Sep;155(3):934-935. doi: 10.1053/j.gastro.2018.08.014. Epub 2018 Aug 10. No abstract available.

PMID:
30098926
50.

Surgeon Assessment of Gastric Cancer Lymph Node Specimens with a Video of Technique.

Ikoma N, Estrella JS, Hofstetter WL, Ajani JA, Fournier KF, Mansfield PF, Skibber JM, Badgwell BD.

J Gastrointest Surg. 2018 Nov;22(11):2013-2019. doi: 10.1007/s11605-018-3880-0. Epub 2018 Jul 27.

PMID:
30054780

Supplemental Content

Loading ...
Support Center